Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
By Drug Type, Liraglutide Segment Accounts for 35.5% Market Share The liraglutide segment is projected to account for 35.5% of the GLP-1 diabetes treatment drugs market in 2025, reaffirming its position as the leading drug type category
This well-established therapeutic use provides strong evidence for NAC's ability to support hepatic glutathione levels
Tirzepatide is similar to the above three drugs in that part of it is a GLP-1 medication
Both medications can independently cause gastrointestinal adverse effects, and their concurrent use may compound these issues
The Chinese development and marketing of efgartigimod are conducted in partnership with Zai Lab [244]
US$ 21.38
US$ 28.85
US$ 24.30
US$ 29.61
US$ 21.47
US$ 21.91
